Navigation Links
Epizyme Publishes Current Review on Targeting Protein Methyltransferases for Personalized Cancer Therapeutics
Date:11/20/2012

CAMBRIDGE, Mass., Nov. 20, 2012 /PRNewswire/ -- Epizyme, Inc., a biopharmaceutical company leading the creation of personalized therapeutics to treat genetically defined cancers, today announced the publication of a contemporary review on targeting protein methyltransferases for personalized cancer therapeutics in the Nature Publishing Group journal Oncogene.

"This publication provides a comprehensive review of the histone methyltransferase (HMT) target class, the genetic alterations in these enzymes that drive specific human cancers and the ongoing efforts to identify and develop potent, selective inhibitors of these enzymes as the basis for novel, personalized cancer therapeutics," said Robert Copeland, Ph.D., Executive Vice President and Chief Scientific Officer of Epizyme. "The review highlights the significant progress that has been made in this field over the past five years and provides a clear foundation for the clinical development of HMT inhibitors (HMTi) that is now underway."

Epizyme has identified 96 histone methyltransferases and determined that 20 play an important role in cancer; these are prime targets for drug development. The company's programs to develop inhibitors for DOT1L for MLL-rearranged leukemia and EZH2 for mutant-bearing Non-Hodgkin lymphoma are examples of Epizyme's approach to creating personalized therapeutics for these genetically defined cancers.

The paper titled, "Targeting genetic alterations in protein methyltransferases for personalized cancer therapeutics," was authored by Robert A. Copeland, Mikel P. Moyer and Victoria M. Richon at Epizyme, and is available online.

About Epizyme

Epizyme is leading the creation of small molecule histone methyltransferase inhibitors (HMTi), a new class of personalized therapeutics for patients with genetically defined ca
'/>"/>

SOURCE Epizyme, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Varian Medical Systems Publishes 2012 Sustainability Report Outlining Environmental, Charitable, Safety and Health Access Achievements
2. American Journal of Medicine Publishes Hypertension Study Comparing the Fixed-Dose Combination of Azilsartan Medoxomil and Chlorthalidone versus Azilsartan Medoxomil Co-administered with Hydrochlorothiazide
3. American Journal of Obstetrics and Gynecology Publishes PeriGen Research on Shoulder Dystocia
4. Pharmspective Publishes New Assessment of Impact of State Exchanges on Key Insurers and Pharma
5. Epilepsia Publishes Results From Two Studies Of Eisais Perampanel
6. Obesity journal publishes new study on lorcaserin, a weight-loss medication recommended for approval by FDA advisory panel
7. HemoShear Publishes Key Review on Human-Relevant Organotypic Systems
8. Largest Prospective Study Shows IVUS-Guided Stent Placement Improves Patient Outcomes with Current Generation of Stents
9. Valeritas Announces The Publication Of A Retrospective Analysis Of Patient-Reported Data On The V-Go In The Current Issue Of Endocrine Practice
10. Novel Apolipoprotein A-I Therapy, CSL112, May Represent New Option for Reducing Recurrent Heart Attack Risk, Early CSL Studies Show
11. Chimerix Presents Data Highlighting Burden Of Care Associated With Current Antiviral Therapies In Stem Cell Transplantation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/6/2015)... UNICANCER pourra identifier ... bénéficier de l,innovation thérapeutique.   ... contenu pour l,Entreprise, annonce que sa solution Luxid® ... de lutte contre le cancer (CLCC), comme module ... (Continuum Soin-Recherche) conduit par la société de conseil ...
(Date:3/5/2015)... 5, 2015  Pfenex Inc. (NYSE MKT: PFNX), ... of biosimilar therapeutics including high value and difficult ... quarter and full year 2014 financial results will ... the market opens for trading.  At 9:00 am ... call to discuss the financial results and provide ...
(Date:3/5/2015)... 2015  IRIDEX Corporation (Nasdaq: IRIX ) today ... January 3, 2015.  , Revenues were $11.8 million ... Company and up 11% from $10.6 million in the 2013 ... record, up 12% from $38.3 million in 2013. , ... from 48.6% in the fourth quarter of the prior year. ...
Breaking Medicine Technology:TEMIS et SWORD accompagnent UNICANCER pour accélérer la recherche par l'analyse sémantique des dossiers patients 2TEMIS et SWORD accompagnent UNICANCER pour accélérer la recherche par l'analyse sémantique des dossiers patients 3TEMIS et SWORD accompagnent UNICANCER pour accélérer la recherche par l'analyse sémantique des dossiers patients 4Pfenex To Report Fourth Quarter and Full Year 2014 Results and Provide Business Update 2IRIDEX Reports 2014 Fourth Quarter, Year-End Results 2IRIDEX Reports 2014 Fourth Quarter, Year-End Results 3IRIDEX Reports 2014 Fourth Quarter, Year-End Results 4IRIDEX Reports 2014 Fourth Quarter, Year-End Results 5IRIDEX Reports 2014 Fourth Quarter, Year-End Results 6IRIDEX Reports 2014 Fourth Quarter, Year-End Results 7IRIDEX Reports 2014 Fourth Quarter, Year-End Results 8
... Hanger Orthopedic Group, Inc. (NYSE: HGR ) ... operations for the quarter ended September 30, 2010, on Wednesday, ... a press release announcing the results for the quarter ended ... close of the market. The conference call is scheduled to ...
... Sept. 30 /PRNewswire-FirstCall/ - Neuro-Biotech Corporation (PINKSHEET: MRES)(OTCQB:MRES) in ... on SymPath(R) and is now ready to give you ... of the Sympathetic Nervous System (SNS). Here is a ... will be available to all patients through their health ...
Cached Medicine Technology:Hanger Orthopedic Group, Inc. Announces Third Quarter 2010 Earnings Release Conference Call 2A brief explanation of Dopamine-Beta-hydroxylase (DBH) - SymPath(R) : In Vitro Diagnostic Test to distinguish anxious disorders from depressive disorders 2A brief explanation of Dopamine-Beta-hydroxylase (DBH) - SymPath(R) : In Vitro Diagnostic Test to distinguish anxious disorders from depressive disorders 3
(Date:3/6/2015)... California (PRWEB) March 06, 2015 Johnson ... million jury verdict on March 5, 2015 in Superior ... According to court documents, a jury of 12 awarded ... suffered from being implanted with an Ethicon TVT Abbrevo ... nine men and three women also awarded $5 million ...
(Date:3/6/2015)... First Choice Emergency Room opened its new Littleton ... 13351 W. Bowles Avenue, Littleton, Colorado and is open 24-7. ... provide the highest quality emergency medical care to the Littleton ... Emergency Room Littleton. , First Choice Emergency Room ... of Commerce and a medical community open house yesterday. ...
(Date:3/6/2015)... 2015 Jvion, the Atlanta-based leader ... a Clostridium Difficile (C Diff) predictive use case ... use case is the latest in a broad ... infections, chronic conditions, and individual illnesses. Using the ... solution flags at risk individuals to help support ...
(Date:3/6/2015)... Truly Nolen, the largest family-owned pest control ... opening of their first independently-owned and operated franchise in ... Fort Mill – Rock Hill, SC area. The ribbon ... their new location. , The Truly Nolen ... in the pest control industry. Locally owned and operated ...
(Date:3/6/2015)... 2015 In a new study conducted at ... reported that shoulder pain was their first mesothelioma symptom. Surviving ... Click here to read it now. , Doctors ... records of 49 mesothelioma patients between 2006 and ... was shoulder pain that first prompted them to see a ...
Breaking Medicine News(10 mins):Health News:Johnson & Johnson Hit with $5.7 Million Verdict in Pelvic Mesh Trial Announces Matthews & Associates Law Firm 2Health News:Johnson & Johnson Hit with $5.7 Million Verdict in Pelvic Mesh Trial Announces Matthews & Associates Law Firm 3Health News:First Choice Emergency Room Opens New Facility in Littleton, Colorado 2Health News:Jvion Predicts Patients at Risk of C Difficile Infection to Reduce Risk and Save Lives 2Health News:First Truly Nolen Franchise Opening in North Carolina 2Health News:New Report Reveals Shoulder Pain Could Signal Early Mesothelioma, According to Surviving Mesothelioma 2
... was supported by the German Research Foundation, brought together scientists ... from the Charit in Berlin. 28 younger persons who had ... equal number of non-smokers participated in this study. Each of ... faces while their brain activity was recorded. The researchers were ...
... logic. But although a computer processor can be dissembled and ... the way our brains process information, says Mark Shein of ... Shein and his supervisors, Prof. Yael Hanein of the School ... of Physics and Astronomy, want to understand the brain,s logic. ...
... has released its global status report on alcohol and ... the discussion in the report of the serious health ... which contributes to accidents, many diseases, and premature deaths. ... that the report was limited almost exclusively to abusive ...
... By Steven Reinberg HealthDay Reporter , MONDAY, July ... comes new research pitting fast food against fruits and veggies, ... found that so-called "food deserts," where there are few or ... to draw locals to the fast food. But in areas ...
... -- Upward social mobility appears to help reduce the risk ... poor or disadvantaged situations, according to a new study. ... at increased risk for high blood pressure, which contributes to ... and socioeconomic data collected from 12,000 same-sex twins who were ...
... presented at the upcoming annual meeting of the Society ... society for research into all aspects of eating and ... promote overeating, weight gain, and insulin resistance. Olanzapine, ... the treatment of schizophrenia and bipolar disorder, has been ...
Cached Medicine News:Health News:Smokers not very receptive to shocking images 2Health News:Cracking the code of the mind 2Health News:Cracking the code of the mind 3Health News:Fast Food Is King of the Neighborhood, Study Reports 2Health News:Fast Food Is King of the Neighborhood, Study Reports 3
More than 200 key diagnostic and treatment tables culled from Tierney's Current Medical Diagnostics and Treatment 2003....
Consists of the print and PDA versions of Harrison's Manual of Medicine 15th Edition. Provides high-end medical content via PDA....
... Knife with BD Xstar Blade includes a ... the blade in prodedure and handling. ... a grind-less process for manufacturing surgical blades. ... and consistency. The arch style, single-bevel ...
A system for all indications, can be used with the OrthoPilot surgical navigation system....
Medicine Products: